The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK

JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms

(2015) Sowmya Parampalli Yajnanarayana et al.   BRITISH JOURNAL OF HAEMATOLOGY

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms

(2015) Kathrin Schönberg et al.   CANCER RESEARCH

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

(2015) R Zeiser et al.   LEUKEMIA

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

(2014) S. Spoerl et al.   BLOOD

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

(2013) T Zhou et al.   LEUKEMIA

Differential requirement for ROCK in dendritic cell migration within lymphatic capillaries in steady-state and inflammation

(2012) M. Nitschke et al.   BLOOD

Non-muscle myosin II takes centre stage in cell adhesion and migration

(2009) Miguel Vicente-Manzanares et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Rapid leukocyte migration by integrin-independent flowing and squeezing

(2008) Tim Lämmermann et al.   NATURE